SCHEMBL6701579

SCHEMBL6701579

O=CCC(c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.46
TDO2 P48775 2/20 0.46
CNR1 P21554 2/20 0.45
CACNA2D1 P54289 4/20 0.44
CACNB1 Q02641 4/20 0.44
CACNA1B Q00975 3/20 0.44
CACNA1C Q13936 3/20 0.44
P2RX7 Q99572 1/20 0.44
CACNA1G O43497 1/20 0.44
CHRNA7 P36544 1/20 0.43
CACNA1A O00555 1/20 0.43
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
BCL2 P10415 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD1 P21728 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864119 0.94 HSD17B10 (0.41) CNR1P2RX7CHRNA7DRD3ATM
SCHEMBL68782 0.87 HTR2A (0.46) L3MBTL1CYP2D6TSHRCYP2C19TDP1
SCHEMBL6339476 0.84 PPARG (0.39) IDO1TDO2CNR1P2RX7SLC6A2
SCHEMBL6699162 0.83 ACP3 (0.47) CNR1CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL6698860 0.83 CYP19A1 (0.55) SLC6A2SLC6A4SLC6A3CYP19A1
SCHEMBL6704538 0.82 IDO1 (0.46) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL6340019 0.82 CHRNB2 (0.55) IDO1CNR1SLC6A2SLC6A4SLC6A3
SCHEMBL28772579 0.82 HTR2A (0.59) CNR1SLC6A2SLC6A4SLC6A3CHRM2
SCHEMBL20902116 0.80 MDM2 (0.39) CACNA2D1CACNB1CACNA1BCACNA1CP2RX7
SCHEMBL2303918 0.80 TDP1 (0.48) L3MBTL1CYP19A1TSHRTDP1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-01-08 US disclosed
CN-1441781-A Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AG (SE) 2003-09-10 CN disclosed
EP-1289957-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2001087839-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity CCR5, CCR2, CCR1 IDO1 905/4885TDO2 4360/4885CNR1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.